Press release
August 6, 2026
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Structure Therapeutics Inc. (GPCR)
First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual amylin and calcitonin receptor agonist) and initiation of MAD clinical trial on